Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Dystrophin (DMD) Pipeline Report 2016: Therapeutics Review of 8 Companies & 26 Molecules - Research and Markets

Research and Markets
Posted on: 11 Oct 16

Research and Markets has announced the addition of the "Dystrophin (DMD) - Pipeline Review, H2 2016" report to their offering.

'Dystrophin (DMD) - Pipeline Review, H2 2016'; Dystrophin (DMD) pipeline Target constitutes close to 26 molecules. Out of which approximately 23 molecules are developed by Companies and remaining by the Universities Institutes.

Furthermore, the publisher says; Dystrophin (DMD) Dystrophin is a cytoplasmic protein. It anchors the extracellular matrix to the cytoskeleton via F-actin. It acts as ligand for dystroglycan. It act as component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma.

The report 'Dystrophin (DMD) - Pipeline Review, H2 2016' outlays comprehensive information on the Dystrophin (DMD) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Dystrophin (DMD) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 1, 10 and 7 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. Dystrophin Overview
  3. Therapeutics Development
  4. Pipeline Products for Dystrophin - Overview
  5. Pipeline Products for Dystrophin - Comparative Analysis
  6. Dystrophin - Therapeutics under Development by Companies
  7. Dystrophin - Therapeutics under Investigation by Universities/Institutes
  8. Dystrophin Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Dystrophin - Products under Development by Companies
  13. Dystrophin - Products under Investigation by Universities/Institutes
  14. Dystrophin - Companies Involved in Therapeutics Development
  • Asklepios BioPharmaceutical, Inc.
  • BioMarin Pharmaceutical Inc.
  • Daiichi Sankyo Company, Limited
  • Genethon
  • Nippon Shinyaku Co., Ltd.
  • PTC Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • WAVE Life Sciences Ltd.

For more information about this report visit

View source version on

Business Wire

Last updated on: 11/10/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.